Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Diarrhea 1Colitis 1Breast Neoplasms 1

Interventions

pembrolizumab 12Cisplatin 11Specimen Handling 9Bevacizumab 7Brachytherapy 6Platinum 5Paclitaxel 5Nivolumab 5Magnetic Resonance Spectroscopy 5Human Papillomavirus DNA Tests 5Colposcopy 5Carboplatin 5atezolizumab 4Gemcitabine 4Fulvestrant 4Surveys and Questionnaires 3Radiotherapy 3Radiation Dose Hypofractionation 3Radiation 3Drug Therapy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tisotumab vedotin 2palbociclib 2lenvatinib 2Topotecan 2Restraint, Physical 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Loperamide × 90 days × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡